Journos News
Thursday, November 20, 2025
  • Login
  • Home
  • Breaking News
  • World News
  • Politics
  • Business
  • Conflict and Crisis
  • Sports
  • Technology
  • Entertainment
  • Health
No Result
View All Result
  • Home
  • Breaking News
  • World News
  • Politics
  • Business
  • Conflict and Crisis
  • Sports
  • Technology
  • Entertainment
  • Health
No Result
View All Result
Journos News
No Result
View All Result
Home Health

FDA Declares Common Cold Medicine Ingredient Ineffective

Why the FDA is Removing a Popular Decongestant

The Daily Desk by The Daily Desk
November 16, 2025
in Health, Health & Wellness, Public Health & Safety
0
Phenylephrine Phase-Out: What It Means for Your Cold Remedies - Jonathan Poet/AP Photo

Effective Alternatives to Cold Medicines Losing FDA Approval - Jonathan Poet/AP Photo

FDA Declares Popular Decongestant Ineffective: What You Need to Know

Changes are coming to the cold and cough medicine aisle at your local pharmacy. The U.S. Food and Drug Administration (FDA) is phasing out phenylephrine, the primary decongestant found in many over-the-counter (OTC) cold medications, as it doesn’t effectively relieve nasal congestion.

What’s Happening?

Phenylephrine is an active ingredient in well-known products like Sudafed, DayQuil, and others. While widely used, its effectiveness has been questioned for years. The FDA recently proposed revoking its use in pills and liquid medications, a decision that could lead drugmakers to either reformulate or discontinue affected products.

This decision is a win for researchers and academics, including University of Florida experts who have been urging the FDA to revisit the drug’s approval since 2007.

For consumers, the phase-out means a shift toward alternatives, such as the older decongestant pseudoephedrine, which has been restricted to behind-the-counter sales since 2006 due to its potential use in methamphetamine production.

Why Does Phenylephrine Fall Short?

Studies show that phenylephrine is ineffective when taken orally because it’s quickly broken down in the stomach, preventing it from entering the bloodstream and reaching the nasal passages.

RELATED POSTS

Global Experts Warn Ultra-Processed Foods Pose Rising Health Risks

Unapproved Peptide Injections Rise in Popularity Despite Regulatory and Safety Concerns

Maximizing Grocery Freshness: Expert Tips for Safe Refrigeration

FDA Removes Long-Standing Safety Warning from Menopause Hormone Therapy Drugs

Tests Detect Botulism Bacteria in ByHeart Baby Formula

Infant Botulism Cases Linked to Recalled Baby Formula Under Federal Investigation

“This is a good drug, but not when it’s swallowed,” explained Leslie Hendeles, professor emeritus at the University of Florida. Even increasing the dosage to 400% of the current recommendation failed to alleviate nasal congestion, and higher doses could pose serious risks, such as dangerously elevated blood pressure.

Why Now?

The FDA’s decision follows unanimous recommendations from federal advisors last year. These advisors reviewed recent large-scale studies as well as older research from the 1960s and 1970s, identifying numerous flaws in the earlier data that supported phenylephrine’s approval.

While phenylephrine nasal sprays remain effective, they are far less popular than pills and syrups, which account for an estimated $1.8 billion in annual U.S. sales.

What Are the Alternatives for Congestion Relief?

Here’s what you can consider:

  1. Behind-the-Counter Options:
    • Medications with pseudoephedrine, such as Sudafed and Claritin-D, are available without a prescription but require a photo ID for purchase.
  2. Nasal Sprays and Rinses:
    • Saline Drops/Rinses: Quickly clear mucus and relieve congestion.
    • Nasal Steroids: Products like Flonase, Nasacort, and Rhinocort provide effective long-term relief for seasonal congestion and allergies. These must be used daily for optimal results.
    • Antihistamine Sprays: Fast-acting sprays like Astepro work well for short-term relief.
  3. Phenylephrine Sprays: These remain available and effective for immediate nasal relief.

What’s Next?

Phenylephrine-based oral medications will remain on shelves for now. The FDA must undergo a public process to remove the drug from its list of approved OTC ingredients. This includes a six-month period for comments from consumers and manufacturers, followed by additional review.

Even after the FDA finalizes its decision, drugmakers will likely have over a year to reformulate or discontinue their products. Manufacturers could also delay the process further by requesting additional hearings.

The Consumer Healthcare Products Association, representing drugmakers, argues that Americans should retain the option to choose these products. However, researchers like Randy Hatton from the University of Florida disagree. “Choosing from something that doesn’t work isn’t really a choice,” Hatton said.

Takeaway

Doctors agree that removing phenylephrine from shelves will simplify the decision-making process for consumers. “People walk into the drugstore and pick something that definitely won’t work,” said Dr. Brian Schroer of the Cleveland Clinic. “This change will guide them toward effective treatments.”

For better congestion relief, consult your pharmacist or healthcare provider about proven alternatives. The transition may take time, but it’s a step toward ensuring that the medications on store shelves truly deliver results.

Source

This article was rewritten by JournosNews.com based on verified reporting from trusted sources. The content has been independently reviewed, fact-checked, and edited for accuracy, neutrality, tone, and global readability in accordance with Google News and AdSense standards.

All opinions, quotes, or statements from contributors, experts, or sourced organizations do not necessarily reflect the views of JournosNews.com. JournosNews.com maintains full editorial independence from any external funders, sponsors, or organizations.

Stay informed with JournosNews.com — your trusted source for verified global reporting and in-depth analysis. Follow us on Google News, BlueSky, and X for real-time updates.

Tags: #AllergyRelief#ColdAndFlu#ColdMedicine#ColdRelief#ConsumerHealth#CoughMedicine#Decongestant#DrugEffectiveness#DrugRegulation#EffectiveMedicine#FDAApproval#FDAProposal#FDAUpdate#FluSeason#HealthCare#HealthcareTips#HealthNews#HealthTips#HealthUpdates#MedicalNews#MedicalResearch#MedicineReformulation#NasalCongestion#NasalSpray#NasalSteroids#OverTheCounterDrugs#PharmacyNews#Phenylephrine#Pseudoephedrine#SalineRinse
ShareTweetSend
The Daily Desk

The Daily Desk

The Daily Desk – Contributor, JournosNews.com, The Daily Desk is a freelance editor and contributor at JournosNews.com, covering politics, media, and the evolving dynamics of public discourse. With over a decade of experience in digital journalism, Jordan brings clarity, accuracy, and insight to every story.

Related Posts

Ultra-Processed Foods Linked to Chronic Diseases, Experts Warn - Getty Images/BBC
Health

Global Experts Warn Ultra-Processed Foods Pose Rising Health Risks

November 19, 2025
Unapproved Peptide Injections Surge as Celebrities Fuel Trend Amid FDA Safety Concerns - AP Photo/Javier Arciga
Health

Unapproved Peptide Injections Rise in Popularity Despite Regulatory and Safety Concerns

November 16, 2025
How to Store Groceries Safely and Extend Freshness - AP Photo/Cheyanne Mumphrey
Food Safety & Nutrition

Maximizing Grocery Freshness: Expert Tips for Safe Refrigeration

November 16, 2025
FDA Removes Longtime Warning from Menopause Hormone Drugs - AP Photo/Evan Vucci
Health

FDA Removes Long-Standing Safety Warning from Menopause Hormone Therapy Drugs

November 11, 2025
Infant Botulism Outbreak Linked to Recalled ByHeart Formula Under FDA Investigation - AP Photo/Jose Luis Magana, File
Health

Tests Detect Botulism Bacteria in ByHeart Baby Formula

November 10, 2025
Infant Botulism Outbreak Linked to Recalled ByHeart Formula Under FDA Investigation - AP Photo/Jose Luis Magana, File
Health

Infant Botulism Cases Linked to Recalled Baby Formula Under Federal Investigation

November 9, 2025
Autoimmune Diseases Explained: Causes, Symptoms, and Treatments - AP Photo/David Goldman
Health

Understanding Autoimmune Diseases: Causes, Risks, and Emerging Treatments

November 8, 2025
Texas Sues Tylenol Makers Over Unproven Autism Link Claims - AP Photo/Michael Conroy, file
Health

TEXAS SUES TYLENOL MAKERS OVER UNPROVEN AUTISM CLAIMS

October 29, 2025
COVID-19 mRNA Vaccines May Boost Cancer Immunotherapy, Study Finds - AP Photo/Juan Karita, File
Health

COVID-19 Vaccines May Boost Cancer Treatment Effectiveness, Study Finds

November 16, 2025
Load More
Next Post
The Man Who Made Suzuki a Global Car Giant: Osamu Suzuki Dies at 94 - Tomohiro Ohsumi/Getty Images

Osamu Suzuki, the Visionary Behind Suzuki’s Success, Dies at 94

85 Dead in Jeju Air Crash: A Nation Grapples with Loss - Yonhap News Agency/Reuters

Tragedy in South Korea: 85 Dead in Plane Crash at Muan Airport

Faulty Heating System Causes Carbon Monoxide Death of Dayle Haddon - Andrea Renault/AFP/Getty Images

Supermodel and Actress Dayle Haddon Dies at 76 from Carbon Monoxide Leak

Journos News delivers globally neutral, fact-based journalism that meets international media standards — clear, credible, and made for a connected world.

CATEGORY

SITE LINKS

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

NEWSLETTER

  • About Us
  • Accessibility Statement
  • Contact Us
  • Privacy Policy
  • Terms and Conditions

© JournosNews.com – Trusted source for breaking news, trending stories, and in-depth reports.
All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Breaking News
  • World News
  • Politics
  • Business
  • Conflict and Crisis
  • Sports
  • Technology
  • Entertainment
  • Health

© JournosNews.com – Trusted source for breaking news, trending stories, and in-depth reports.
All rights reserved.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.